Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANIP
stocks logo

ANIP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
232.50M
+22%
1.955
+19.92%
210.16M
+6.61%
1.684
-0.94%
230.99M
+9.28%
1.992
+10.67%
Estimates Revision
The market is revising Upward the revenue expectations for ANI Pharmaceuticals, Inc. (ANIP) for FY2025, with the revenue forecasts being adjusted by 3.61% over the past three months. During the same period, the stock price has changed by -13.22%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.39%
In Past 3 Month
Stock Price
Go Down
down Image
-13.22%
In Past 3 Month
Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 113.50 USD with a low forecast of 103.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 113.50 USD with a low forecast of 103.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 82.740
sliders
Low
103.00
Averages
113.50
High
121.00
Current: 82.740
sliders
Low
103.00
Averages
113.50
High
121.00
Guggenheim
Vamil Divan
Buy
maintain
$114 -> $115
2025-11-10
Reason
Guggenheim
Vamil Divan
Price Target
$114 -> $115
2025-11-10
maintain
Buy
Reason
Guggenheim analyst Vamil Divan raised the firm's price target on ANI Pharmaceuticals to $115 from $114 and keeps a Buy rating on the shares. The firm is updating its model after the company reported "yet another beat and raise quarter" and following its follow-up conversation with management.
JPMorgan
NULL -> Overweight
maintain
$95 -> $115
2025-09-24
Reason
JPMorgan
Price Target
$95 -> $115
2025-09-24
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on ANI Pharmaceuticals to $115 from $95 and keeps an Overweight rating on the shares. The firm remains bullish on the company's Cortrophin Gel, which it views as a "highly-durable" growth driver for ANI.
H.C. Wainwright
Brandon Folkes
maintain
$93 -> $121
2025-09-17
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$93 -> $121
2025-09-17
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on ANI Pharmaceuticals to $121 from $93 and keeps a Buy rating on the shares. The firm says Cortrophin Gel script data continues to track ahead of its forecasts. In addition, the the addressable market for Cortrophin is larger larger previously modeled, with 500,000 acute gout flares offering a "very significant opportunity, along with multiple other indications," the analyst tells investors in a research note.
Guggenheim
Vamil Divan
maintain
$86 -> $114
2025-09-08
Reason
Guggenheim
Vamil Divan
Price Target
$86 -> $114
2025-09-08
maintain
Reason
Guggenheim analyst Vamil Divan raised the firm's price target on ANI Pharmaceuticals to $114 from $86 and keeps a Buy rating on the shares after the company reported "very impressive" Q2 earnings last month. The firm continues to see ANI Pharmaceuticals as "uniquely positioned" to deliver fundamental upside driven by the firm's strengthened bullish view on Cortrophin Gel, while also being "relatively immune" to many of the macro uncertainties that are impacting the broader biopharma segment, the analyst tells investors.
Truist
Hold
maintain
$65 -> $77
2025-08-11
Reason
Truist
Price Target
$65 -> $77
2025-08-11
maintain
Hold
Reason
Truist raised the firm's price target on ANI Pharmaceuticals to $77 from $65 but keeps a Hold rating on the shares after its Q2 earnings beat. The management boosted the product's guide which also coincided with commentary heard from the competition, even though the company's Iluvien market access challenges remain and generics performed inline, the analyst tells investors in a research note. Truist adds that the ANI valuation at 10-times EBITDA warrants a neutral stance.
Piper Sandler
David Amsellem
maintain
$80 -> $94
2025-08-08
Reason
Piper Sandler
David Amsellem
Price Target
$80 -> $94
2025-08-08
maintain
Reason
Piper Sandler analyst David Amsellem raised the firm's price target on ANI Pharmaceuticals to $94 from $80 and keeps an Overweight rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for ANI Pharmaceuticals Inc (ANIP.O) is 10.67, compared to its 5-year average forward P/E of 12.84. For a more detailed relative valuation and DCF analysis to assess ANI Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
12.84
Current PE
10.67
Overvalued PE
16.91
Undervalued PE
8.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.25
Undervalued EV/EBITDA
7.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.87
Current PS
0.00
Overvalued PS
2.18
Undervalued PS
1.56
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 5722.64% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 5722.64% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ANIP News & Events

Events Timeline

(ET)
2025-12-01
07:19:00
ANI Pharmaceuticals Chairman Walsh Retires; Haughey Elected New Chairman
select
2025-11-07 (ET)
2025-11-07
06:55:07
ANI Pharmaceuticals increases FY25 adjusted EPS forecast to $7.37-$7.64, up from $6.98-$7.35
select
2025-11-07
06:52:59
ANI Pharmaceuticals announces Q3 adjusted earnings per share of $2.04, surpassing consensus estimate of $1.77.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04NASDAQ.COM
Ensign Group Strengthens Presence in Three U.S. States Through Facility Acquisitions

  • Acquisition Details: The Ensign Group, Inc. has acquired four skilled nursing facilities, effective December 1, 2025, increasing its portfolio to 373 healthcare operations across 17 states, including facilities in Colorado, Kansas, and Arizona.

  • Strategic Growth: The acquisitions are part of Ensign's strategy to enhance patient-centered care and strengthen its presence in underserved communities, contributing significantly to its revenue growth, particularly in the Skilled Services segment.

  • Financial Performance: Ensign's shares have increased by 24.4% over the past year, outperforming the industry average, and the company maintains a Zacks Rank #2 (Buy), indicating strong market confidence.

  • Comparative Stock Performance: Other top-ranked stocks in the medical sector, such as Collegium Pharmaceutical, ANI Pharmaceuticals, and Intuitive Surgical, have also shown significant earnings growth and stock performance, with each holding a Zacks Rank #1 (Strong Buy).

[object Object]
Preview
7.5
12-03NASDAQ.COM
REGN and Tessera Partner to Create Gene-Editing Treatment for AATD

  • Collaboration with Tessera Therapeutics: Regeneron Pharmaceuticals has entered a collaboration with Tessera Therapeutics to develop TSRA-196, a gene editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), sharing development costs and profits equally.

  • Regulatory Approvals and Product Performance: Regeneron has received FDA approval for Eylea HD and a label expansion for Libtayo, while facing challenges with declining Eylea sales due to competition, prompting the development of a higher dose version.

  • Financial Outlook and Stock Performance: Regeneron’s stock has increased by 5.3% year-to-date, but the decline in Eylea sales poses a significant challenge, despite positive developments in its oncology portfolio and partnerships.

  • Market Comparisons and Rankings: Regeneron holds a Zacks Rank #3 (Hold), while competitors like CorMedix and ANI Pharmaceuticals have better rankings and have shown significant stock performance improvements in recent months.

[object Object]
Preview
8.5
12-03NASDAQ.COM
BHC Shares Rise Following Solta's Acquisition of Shibo's Aesthetics Distribution Division

  • Bausch Health Acquisition: Bausch Health, Inc. shares rose 11% following the acquisition of Wuhan Shibo Zhenmei Technology, enhancing Solta Medical's distribution capabilities in China's growing aesthetics market.

  • Financial Performance: Bausch Health reported better-than-expected third-quarter results, with Solta Medical's revenues increasing by 25% year-over-year, although the company still faces significant long-term debt of $21 billion.

  • Market Positioning: The acquisition positions Solta Medical to meet rising demand for aesthetic treatments in China, improving operational efficiency and revenue potential in the region.

  • Stock Rankings: Bausch Health holds a Zacks Rank #3 (Hold), while other biotech stocks like CorMedix, Amicus Therapeutics, and ANI Pharmaceuticals are ranked #1 (Strong Buy), indicating stronger market performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ANI Pharmaceuticals Inc (ANIP) stock price today?

The current price of ANIP is 82.74 USD — it has increased 0.08 % in the last trading day.

arrow icon

What is ANI Pharmaceuticals Inc (ANIP)'s business?

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

arrow icon

What is the price predicton of ANIP Stock?

Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 113.50 USD with a low forecast of 103.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ANI Pharmaceuticals Inc (ANIP)'s revenue for the last quarter?

ANI Pharmaceuticals Inc revenue for the last quarter amounts to 227.81M USD, increased 53.58 % YoY.

arrow icon

What is ANI Pharmaceuticals Inc (ANIP)'s earnings per share (EPS) for the last quarter?

ANI Pharmaceuticals Inc. EPS for the last quarter amounts to 1.13 USD, decreased -188.98 % YoY.

arrow icon

What changes have occurred in the market's expectations for ANI Pharmaceuticals Inc (ANIP)'s fundamentals?

The market is revising Upward the revenue expectations for ANI Pharmaceuticals, Inc. (ANIP) for FY2025, with the revenue forecasts being adjusted by 3.61% over the past three months. During the same period, the stock price has changed by -13.22%.
arrow icon

How many employees does ANI Pharmaceuticals Inc (ANIP). have?

ANI Pharmaceuticals Inc (ANIP) has 897 emplpoyees as of December 05 2025.

arrow icon

What is ANI Pharmaceuticals Inc (ANIP) market cap?

Today ANIP has the market capitalization of 1.86B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free